G protein-coupled receptor kinases (GRKs) constitute a family of six mammalian serine/threonine protein kinases that phosphorylate agonist-bound, or activated, G protein-coupled receptors (GPCRs) as their primary substrates. GRK-mediated receptor phosphorylation rapidly initiates profound impairment of receptor signaling, or desensitization. This review focuses on the regulation of GRK activity by a variety of allosteric and other factors: agonist-stimulated GPCRs, βγ subunits of heterotrimeric GTP-binding proteins, phospholipid cofactors, the calcium-binding proteins calmodulin and recoverin, posttranslational isoprenylation and palmitoylation, autophosphorylation, and protein kinase C-mediated GRK phosphorylation. Studies employing recombinant, purified proteins, cell culture, and transgenic animal models attest to the general importance of GRKs in regulating a vast array of GPCRs both in vitro and in vivo.
Characterizing desensitization by time course and stimulus specificity provides perspective on the role of GRKs in this phenomenon. Within milliseconds to minutes of agonist challenge, cells can diminish or virtually eliminate (7) (8) (9) (10) their agonist-evoked responses, in a process that involves phosphorylation of the receptors on one or more intracellular domains. After several hours of agonist exposure, the short-term desensitization just described is augmented by receptor down-regulation, a process in which the cellular complement of stimulated receptors is decreased by a combination of protein degradation, transcriptional, and posttranscriptional mechanisms (11) . The cellular response to a given agonist may be desensitized by cellular exposure to that agonist itself, in a process descriptively dubbed homologous desensitization. Alternatively, desensitization of the response to a given agonist may be engendered by cellular exposure to agonists for distinct receptor signaling systems, in a process termed heterologous desensitization. Potentially affecting multiple receptor systems, heterologous desensitization involves phosphorylation of GPCRs by second-messenger-dependent kinases, such as cyclic AMP (cAMP)-dependent protein kinase and protein kinase C (PKC). Receptor phosphorylation by these kinases, as an isolated event, substantially impairs the ability of purified receptors to stimulate their G proteins (12, 13) .
The discovery of GRKs emerged from investigations of mechanisms responsible for short-term, homologous desensitization of the β 2 -adrenergic receptor (β 2 AR) and rhodopsin, the prototypic "light receptor." With the β 2 AR, agonist-induced receptor phosphorylation associated with homologous desensitization (14) was found to occur even in cells genetically lacking cAMPdependent protein kinase (15) . The enzyme responsible for this activity was purified from these cells (16) as well as from bovine brain (17) and was named β-adrenergic receptor kinase (later, GRK2). Rhodopsin kinase (GRK1) was identified earlier (18) as the enzyme responsible for phosphorylating lightbleached (agonist-activated) rhodopsin in rod outer segments. Subsequently, GRK1-mediated phosphorylation of rhodopsin was associated with desensitization of the rhodopsin/G T /cGMP phosphodiesterase system (19) . Identification of the GRK family followed the molecular cloning of cDNAs for GRK2 (20) and then GRK1 (21) . Homology (22) (23) (24) (25) or positional (26) cloning strategies subsequently identified the other four known mammalian GRKs (see below). The GRK family of serine/threonine kinases shares the unusual feature of phosphorylating specifically the agonist-occupied, or activated, conformation of G protein-coupled receptors.
The current model of GRK action ( Figure 1) proposes that a receptor phosphorylated by a GRK can subsequently bind stoichiometrically to one of a family of cytoplasmic inhibitory proteins known as arrestin isoforms (27, 28) in the retina or β-arrestin-1 (29-31) and β-arrestin-2 (8, 31) isoforms in extraretinal tissues. As a result of arrestin or β-arrestin binding, the receptor is prevented from activating its G protein and, therefore, its effector(s). This two-step process of GRK-initiated desensitization can reduce by as much as 70-80% the ability of fully activated β 2 ARs or rhodopsin to activate their respective G proteins (7, 8) . Furthermore, the binding of nonretinal arrestins to GRK-phosphorylated receptors is believed to initiate G protein-coupled receptor endocytosis, or sequestration (32) , into recycling endosomes (33) . In this subcellular location, G protein-coupled receptors appear to be dephosphorylated by a membraneassociated phosphatase (34) , in the process of resensitization, before returning to the cell surface in signaling-competent form.
The importance of GRKs in homologous desensitization of G protein-coupled receptors has been highlighted over the past 12 years by the convergence of several lines of evidence. First, at a time when cAMP-dependent kinase was believed to be important in β 2 AR desensitization, homologous desensitization and agonist-induced phosphorylation of the β 2 AR was shown to transpire-via a GRK2-initiated process (35) -in mutant cells that lacked the cAMP-dependent protein kinase (15) . Second, diminished agonist-induced receptor phosphorylation and/or desensitization was observed when cloned receptors were mutated (10, 36, 37) at serine and threonine residues thought-or subsequently demonstrated (38, 39) -to be sites for GRK phosphorylation. Third, chemical or genetic inhibition of GRK action in cells or transgenic animals has either blunted receptor desensitization or potentiated receptor function. Lastly, augmentation of GRK activity by enzyme overexpression has amplified receptor desensitization or attenuated receptor function in transfected cells and transgenic animals.
THE FAMILY OF GRKs

Structure, Evolution, and Enzymology
Six mammalian cDNAs encoding members of the GRK subfamily of serine/threonine kinases (EC.2.7.1-) have been identified to date: GRK1 (rhodopsin kinase) (21) ; GRK2 (β-adrenergic receptor kinase-1) (20) ; GRK3 (β-adrenergic receptor kinase-2) (22); GRK4 (IT-11) (26); GRK5 (23, 24) ; and GRK6 (25) . (The original names of these enzymes are given in parentheses.) With the exception of GRK1 [which is found almost exclusively in retina (21) ] and GRK4 [which is expressed at significant levels only in testes (26, 40) ], GRKs has not yet bound agonist (A); heterotrimeric G protein (αβγ ); and effector (E). GRK5 adheres to the cytosolic surface of the plasma membrane (stippled rectangle) via binding to phosphatidylinositol-bisphosphate (P 2 ) with its N-terminal domain and any phospholipid (stippled circle) with its C-terminal domain. Phospholipid-bound GRK5 undergoes autophosphorylation (P), which is required for receptorphosphorylating activity. Stage 2 (activation): Activated by agonist, the receptor (R * ) in turn activates the G protein, which dissociates into βγ and active, GTP-bound α (α * ) subunits. The GTP-bound α subunit stimulates the effector(s) (E) to produce second messenger(s), which in turn can activate protein kinase C (PKC) isoforms, among other proteins. G βγ subunits, along with PIP 2 (P 2 ), facilitate the translocation of GRK2 to the plasma membrane, where GRK2 binds to the activated receptor. Phospholipid-bound GRK5, by contrast, binds to the activated receptor without the assistance of G βγ subunits. Phospholipid binding by GRK5 is inhibited by calcium/calmodulin (CAM). Whereas the receptor-phosphorylating activity of GRK2 is enhanced if the GRK2 is phosphorylated by PKC, the receptor-phosphorylating activity of GRK5 is diminished if the GRK5 is phosphorylated by PKC. Stage 3 (signal termination): The receptor-bound GRKs phosphorylate (P) the activated receptors, which can then bind stoichiometrically to a β-arrestin molecule. Bound to a β-arrestin (or arrestin) molecule, the phosphorylated, activated receptor can no longer activate G proteins. Second-messenger signaling terminates as the G α subunit hydrolyzes GTP to GDP, thereby inactivating itself, and again binds to the G βγ subunits. Throughout the schematic, dark shading is used to denote activated proteins.
are ubiquitously expressed (41) . GRK4 is the only member of this family shown to undergo alternative splicing (40, 42) . Four splice variants exist, with the alternatively spliced exons occurring in the amino and carboxyl termini (40) .
Evolutionary conservation among GRKs isolated from nematodes, insects, and mammals emphasizes their biological importance. GPRK1 and wj283.2 encode, respectively, Drosophila (43) and Caenorhabditis elegans (44) proteins with 62% and 51% homology to bovine GRK2. Similarly, GPRK2 and f19c6.1 encode Drosophila and C. elegans proteins with 50-53% homology to bovine GRK5 (43, 44) . Among the six mammalian GRKs, amino acid sequence similarity is 53-93%, with GRK1 and GRK2 being the most divergent.
GRKs are most closely related to PKC and cAMP-dependent protein kinase families (PKAs), although sequences within some GRK catalytic subdomains (I, II, VI, VII, and VIII) (45) are strikingly different from these enzymes. Most notable among these differences is that found in the ATP-binding region (46) of subdomain VII, where the DFG (Asp Phe Gly) sequence of most serine/threonine kinases (45) is replaced by DLG (Asp Leu Gly) in GRKs. Based on sequence and functional similarities, the GRK family has been divided into three subfamilies: (a) GRK1, (b) GRK2 or β-adrenergic receptor kinase (βARK) (GRK2 and GRK3), and (c) GRK4 (GRK4, GRK5, and GRK6) (47) . Members of the GRK2 subfamily share approximately 84% sequence similarity, and members of the GRK4 subfamily share approximately 70% sequence similarity.
Structurally, GRKs contain a centrally located 263-266 amino acid catalytic domain flanked by large amino-and carboxyl-terminal regulatory domains. The amino-terminal domains of GRKs share a common size (∼185 amino acids) and demonstrate a fair degree of structural homology. These observations have prompted the speculation that amino-terminal domains may perform a common function in all GRKs, potentially that of receptor recognition (48) . In contrast, the carboxyl-terminal domain of GRKs is highly variable in both length and structure. GRK1 contains a carboxyl terminus of approximately 100 amino acid residues, the GRK2 subfamily approximately 230 amino acid residues, and the GRK4 subfamily approximately 130 amino acid residues. This region of GRKs represents the site of several posttranslational modifications and regulatory protein/protein interactions. It appears to be involved in the membrane and receptor targeting of these enzymes.
Functionally, GRKs exhibit several hallmark characteristics:
1. They preferentially phosphorylate activated (agonist-occupied) rather than inactive or antagonist-occupied G protein-coupled receptor (GPCR) substrates.
2. Interaction of GRKs with their activated receptor substrates potently activates these enzymes.
3. GRK-mediated GPCR phosphorylation requires the participation of regulatory mechanisms responsible for the membrane localization and receptor targeting of these enzymes.
Catalytically, GRKs have demonstrated no clear consensus sequence in their receptor substrates, even though GRK-mediated GPCR phosphorylation has been demonstrated to occur on specific residues in the cytoplasmic carboxyl tail [rhodopsin (39) , β 2 AR (38)] or the third intracellular loop [m2 muscarinic acetylcholine receptor (49) , α 2A -adrenergic receptor (50)] of several receptors. However, in some cases, the putative or sequenced sites of GRK phosphorylation have pairs of acidic residues located at the amino-terminal side of the most amino-terminal phosphorylated residue (38, (50) (51) (52) . These findings contrast somewhat with peptide phosphorylation studies, which have revealed apparent GRK substrate specificity. While GRK1 and GRK2 most actively phosphorylate peptides containing acidic residues flanking serines or threonines on the carboxyl-or amino-terminal sides, respectively (53), GRK5 and GRK6 most actively phosphorylate peptides containing basic residues amino terminal to the serine target residues (54, 55) . GRK-mediated phosphorylation of peptides may proceed in a sequential manner (51, 52, 56) -that is, phosphorylation of a residue adjacent to acidic amino acids appears to be required for the GRKmediated phosphorylation of more distal serine/threonine residues, in a manner analogous to the behavior of casein kinase II and glycogen synthase kinase 3 (57, 58) . Since the stoichiometry of GRK-mediated phosphorylation of most GPCRs in intact cells approximates 1 mole phosphate/mole receptor (59) (60) (61) (62) , however, the relevance to receptors of sequential substrate phosphorylation remains uncertain.
REGULATION OF GRKS
GRK-Mediated Phosphorylation of GPCR Substrates: The Agonist-Occupied Receptor/GRK Ternary Complex
A defining feature of the GRK family is its substrate specificity. GRKs phosphorylate GPCRs, but only when the receptors are in their activated (agonistoccupied) state. What mechanisms underlie the specific recognition and phosphorylation of activated receptors by GRKs? Agonist occupancy of GPCRs is accompanied by a change in receptor conformation (6) . Thus, GRKs may simply interact with and phosphorylate regions of the receptor exposed following receptor activation. This simple model of GRK/GPCR complex formation has been abandoned in the face of a considerable body of evidence suggesting a highly complex and specific kinase/substrate interaction that has functional consequences not only for the receptor but also for the kinase itself.
Several lines of evidence indicate that GRKs interact with receptor substrates at sites distinct from their sites of phosphorylation:
1. Compared with agonist-occupied receptors, synthetic peptides serve as extremely poor substrates for these enzymes. V max :K m ratio values for synthetic peptide phosphorylation are 100-100,000-fold lower than values for agonist-occupied GPCRs (53) (54) (55) 63 ).
2. GRK-mediated receptor phosphorylation can be inhibited by peptides derived from rhodopsin or β 2 AR intracellular domains that are remote from the actual sites of receptor phosphorylation (63) (64) (65) . Moreover, receptor peptides specifically inhibit phosphorylation of receptor, as opposed to peptide, substrates (63) . These results indicate that receptor peptides specifically block the GRK/GPCR interaction rather than directly inhibit the GRKs.
3. GRK-mediated peptide phosphorylation is markedly enhanced in the presence of activated receptors (66) (67) (68) .
The three lines of evidence outlined above support a model in which receptor domains other than the site of GRK phosphorylation are primarily responsible for mediating the interaction between the GRK and its GPCR substrate.
What regions of a GPCR substrate interact with the GRK? And what functional consequences does this multisite interaction have for GRK function? Insight into the functional consequences that such multisite interactions may have for GRK activity first came from studies with rhodopsin, when it was demonstrated that GRK1-mediated phosphorylation of a peptide substrate is significantly enhanced (>100-fold) specifically in the presence of activated rhodopsin (66, 67) . This effect was achieved with an enzymatically digested form of rhodopsin, which lacked the carboxyl-terminal domain residues phosphorylated by GRK1 (66) . These results confirm that GRK1 interacts with receptor domains distinct from those that serve as phosphate acceptors. Furthermore, these results demonstrate that an activated GPCR serves not only as a GRK substrate but also as a GRK activator. The interaction of GRK2 with either activated rhodopsin or β 2 AR (68) has also been demonstrated to lead to allosteric activation of this enzyme. Notably, however, PKA is not allosterically activated by occupied GPCR substrates (68) . Enhancement of GRK activity by activated GPCRs is thus proposed to be a feature common among, and specific to, members of the GRK family of enzymes. The ability of activated GPCRs to enhance GRK activity toward peptide substrates raises the possibility that in a cellular setting, GRKs may phosphorylate nonreceptor substrates following receptor activation.
The third intracellular loop of GPCRs has been implicated in GRK activation, because proteolysis of this region in rhodopsin prevents allosteric activation of GRK1 (66) . Regions of the third intracellular loop in close proximity to the transmembrane domains of GPCRs are also proposed to represent sites participating in the interaction with, and activation of, heterotrimeric G proteins (69) . In this respect, it is of particular interest that mastoparan, a peptide activator of G proteins, has been shown to stimulate GRK1-mediated phosphorylation of peptide substrates: The V max :K m ratio increases 10-fold (66) . Similarly, GRK2-mediated phosphorylation of a fusion protein encompassing the third loop of the m2 muscarinic acetylcholine receptor is dramatically enhanced in the presence of mastoparan: The V max :K m ratio increases 1000-fold (70) . These results are consistent with the hypothesis that domains within the receptor responsible for G-protein activation following agonist occupancy may also bind to and activate GRKs. Thus the same regions of the GPCR responsible for initiating signal transduction may also play a role in facilitating signal termination mediated by GRKs.
The Pleckstrin Homology Domain of GRK2 and GRK3
GRK2 and GRK3 contain within their carboxyl termini an approximately 100-amino acid protein module termed a pleckstrin homology (PH) domain. This recently described region of sequence homology has been identified in at least 70 different proteins, many of which can be clustered into groups of functionally related molecules. PH domains are found in serine/threonine-specific kinases (e.g. GRK2, GRK3, RAC, and Nrk); tyrosine-specific kinases (such as Btk, Tec-A, and tlk); all of the known mammalian phospholipase Cs; regulators of small GTP-binding proteins [i.e. GTPase-activating proteins (GAPs) and guanine nucleotide-releasing factors (GRFs)]; and a number of cytoskeletal proteins (including β-spectrin) (71, 72) . Sequence identity between PH domains is limited. Only a single amino acid, a tryptophan residue, is invariant in all sequences. However, PH domain alignment shows six blocks of homology containing conserved hydrophobic residues; the blocks are separated by variable-length inserts (71) .
The classification of PH domains as discrete protein modules is supported by analysis of their molecular structures. With nuclear magnetic resonance (NMR) and X-ray crystal analysis, the structures for several PH domains from different proteins (73) (74) (75) (76) (77) (78) (79) (80) (81, 82) . A potential molecular basis for this agonist-stimulated redistribution of GRK2 emerged from in vitro studies demonstrating that the G βγ binds the carboxyl terminus of this enzyme (83, 84) . G-protein γ subunits are modified by isoprenylation, in which a 15-carbon farnesyl [in the case of γ 1 (retinal G γ )], or more commonly a 20-carbon geranylgeranyl isoprenoid moiety, is covalently attached to the cysteine residue of a CAAX motif. Isoprenylation of γ subunits is responsible for the membrane targeting of G βγ (85) . Association of G βγ with the carboxyl terminus of GRK2 promotes in vitro the association of GRK2 with lipid vesicles and rod outer-segment membranes (83, 86, 87) . Membrane association dramatically enhances GRK2-mediated phosphorylation of activated receptors reconstituted in phospholipid vesicles, such as the β 2 AR and the m2 muscarinic acetylcholine receptor, as well as rhodopsin in rod outer-segment membranes (83, (86) (87) (88) (89) . On the basis of these observations, a model has been proposed in which agonist occupancy of a GPCR leads to the activation of heterotrimeric G proteins and the release of the free G βγ dimer. The membrane-localized G βγ subsequently interacts with GRK2 and serves to target this enzyme to its membrane-incorporated receptor substrate. Evidence for the operation of such a mechanism in intact cells has recently been obtained with the demonstration by coimmunoprecipitation of an agonist-specific association between GRK2 or GRK3 and G βγ (82) .
Compared with other GRKs, members of the GRK2 subfamily have extended carboxyl termini. The presence of the G βγ -binding site within this region is consistent with the identification of these enzymes as the only G βγ -regulated GRKs to be identified to date. G βγ binds to an approximately 125-amino acid region (residues 546-670), the distal end of which is located 19 residues from the carboxyl terminus of GRK2 (84) . This region encompasses the PH domain of GRK2 (residues 553-656). Specifically it is the carboxyl-terminal half of the PH domain, and residues extending beyond the end of the recognized PH domain, that are involved in G βγ binding (90, 91) . Consistent with this observation, G βγ will bind to a 28-amino acid GRK2 peptide that comprises 9 amino acids from the carboxyl terminus of the PH domain and 19 amino acids from the remaining carboxyl-terminal domain (84) . Mapping the G βγ -binding domain to regions including and extending beyond the carboxyl-terminal region of the PH domain suggests that G βγ binding may be a property common to a subset of PH domain-containing proteins-those containing the appropriate sequence determinants adjacent to the PH domain (90) . The amino terminus of PH domains forms a hydrophobic β-barrel pocket (72) . This structure is similar to that of the retinoid-binding protein family, all of which bind lipophilic molecules (92, 93) . Indeed, in vitro, isolated PH domains display specific binding to the charged lipid phosphatidylinositol-4,5-bisphosphate (PIP2) (94) . PIP 2 binds to the amino terminus of a GRK2 PH domain lacking carboxyl-terminal sequences required for G βγ binding (91, 94) . This observation immediately suggests that the PH domain of GRK2 is the site of multiple ligand interactions.
What role does PIP 2 play in regulating GRK2 activity? An initial survey of published literature reveals a confusing picture, with reports of both enhancement and inhibition of GRK2 activity by PIP 2 (87, (95) (96) (97) . Differences in experimental procedures, principally the concentration of PIP 2 used, probably account for these disparate findings. A clearer understanding of the regulatory role of PIP 2 is obtained when experiments performed at physiological concentrations of PIP 2 (98) are examined.
GRK2 activity has traditionally been assessed in vitro with purified GPCRs reconstituted in vesicles composed of multiple lipids, or alternatively with rhodopsin in rod outer-segment membranes-again, a heterogeneous lipid environment. Under these conditions, GRK2 catalyzes agonist-dependent GPCR phosphorylation, which is enhanced on addition of G βγ subunits (83, 84, 86, 88, 89) . To assess the role of PIP 2 in the regulation of GRK2, this traditional approach required modification such that receptor substrates are reconstituted in lipid vesicles or detergent/lipid micelles of defined lipid composition. This change in experimental approach revealed a previously unappreciated aspect of GRK regulation: that GRKs are lipid-dependent enzymes. Indeed, GRK2 fails to phosphorylate activated GPCRs when these receptor substrates are reconstituted in vesicles composed of pure phosphatidylcholine (PC) (87, 95, 97) . This null background facilitated the demonstration that both PIP 2 and G βγ are required for effective GRK2-mediated βAR (87) and m2 muscarinic acetylcholine receptor phosphorylation (97) . The synergistic activation of GRK2 observed in the presence of both PH domain ligands suggests their cooperative binding to the PH domain of GRK2. It remains to be determined whether the coordinate binding of multiple ligands is a feature shared with other PH domains.
The synergistic enhancement of GRK2-mediated GPCR phosphorylation observed in the presence of G βγ and PIP 2 cannot be accounted for by G βγ -and/or PIP 2 -mediated direct activation of the enzyme, because GRK2-mediated phosphorylation of soluble substrates is at best only modestly (approximately twofold) affected by these ligands (70, 86, 87, 95) . How then does PH domain ligand binding facilitate GRK2-mediated receptor phosphorylation? The coordinated presence of G βγ and PIP 2 promotes membrane association of GRK2 (87) . By restricting diffusion of GRK2 from three dimensions in solution to two dimensions at the surface of the membrane, PH domain ligands are proposed to facilitate the interaction of GRK2 with its receptor substrates. G βγ -and PIP2-mediated membrane localization may thus play an important role in promoting GRK2-mediated GPCR phosphorylation.
G βγ appears to play an additional role above and beyond the simple targeting of GRK2 to the membrane. G βγ binding specifically targets GRK2 to its activated receptor substrate and promotes the GPCR-mediated allosteric activation of this enzyme (70, 86, 99) . Thus, although G βγ does not significantly affect the rate of GRK2-mediated peptide phosphorylation in the absence of additional activators, G βγ addition dramatically promotes peptide phosphorylation observed in the presence of activated GPCRs or mastoparan (a peptide mimic of activated receptors) (70, 86, 99) . In other words, GPCR-mediated allosteric activation of GRK2 occurs more effectively in the presence of G βγ .
THE βγ SUBUNIT SPECIFICITY OF THE PH DOMAINS OF GRK2 AND GRK3
Although GRK2 and GRK3 are highly homologous proteins, they are only 39% identical across a span of 18 amino acids (residues 648-665) within the G βγ -binding domain (100) . Mammalian cDNAs encoding 6 G β subunits (101) and 12 G γ subunits (102) have been identified, combining to form a multitude of potential G βγ combinations. The presence of a variable domain within the G βγ -binding site of GRK2 and GRK3 suggests the potential for specificity of G βγ isoform binding. This hypothesis has been confirmed in solution phase and in cellular studies (82) . Incubation of fusion proteins encompassing the carboxyl termini of either GRK2 or GRK3 with a diverse mixture of G βγ 's purified from bovine brain reveals that G β3 binds to the carboxyl terminus of GRK3 but not of GRK2. In contrast, G β1 and G β2 bound with apparently equal affinities to both GRK2 subfamily members (82) . Notably, in a separate study, peptides derived from GRK2 or GRK3 displayed no selectivity of G β binding (100), suggesting that determinants outside of the 18-amino acid region of these enzymes are responsible for conferring specificity.
The specificity of the carboxyl terminus of GRK3 for G β3 was confirmed through the use of purified recombinant G β1γ 5 and G β3γ 5 (82) . Although G β1γ 5 bound to both GRK2 and GRK3 fusion proteins, G β3γ 5 bound exclusively to the GRK3 (82) . The nature of the G β subunit appears to be the primary determinant regulating the specificity of the GRK2 and GRK3 G βγ interactions.
The G γ subunits of G βγ have been proposed to play a role in determining the affinity of the GRK/G βγ interaction. Thus purified recombinant G β1 or G β2 complexed with γ 2, γ 5, or γ 7 is more efficacious at promoting GRK2-and GRK3-mediated phosphorylation of activated receptor substrates than when G β1 or G β2 is complexed to G γ 3 (103, 104) . Although these data may indicate a lower affinity of G β1γ 3 and G β2γ 3 for GRKs, they may also reflect an impaired ability of these G βγ combinations to interact with activated receptor substrates.
That GRK2 and GRK3 exhibit specificity for distinct G βγ combinations in intact cells has been shown in studies that monitored GRK/G βγ complex formation following agonist occupancy of GPCRs. It has also been shown by the specific blockade of GPCR-mediated desensitization by peptides derived from the G βγ -binding domain of GRK2 and GRK3 (105) . The formation of a GRK/G βγ complex in cells overexpressing either GRK2 or GRK3 following activation of GPCRs was monitored by probing GRK immunoprecipitates for the presence of G β . The complexing of G βγ with both GRK2 and GRK3 was observed following agonist activation of either the lysophosphatidic acid receptor or the β 2 AR. In marked contrast, complexing of G βγ with only GRK3 was observed following activation of thrombin receptors (82) . This observation suggests that in the cell line tested, GRK3 preferentially interacts with the specific G βγ combination prevalent in the G protein that couples to thrombin receptors. The coupling of specific receptors to distinct G βγ combinations has been suggested from experiments utilizing antisense mRNAs directed against G β and G γ subunits (106) . Because G β3 binds to GRK3, but not to GRK2, it is tempting to speculate whether this G β subunit plays a role in thrombinmediated signal transduction. The inhibition of neuronal voltage-dependent Ca 2+ channels mediated by α 2 -adrenergic receptors desensitizes, via a GRK3-specific mechanism, following prolonged exposure to neurotransmitter (105) . A peptide derived from the G βγ -binding domain of GRK3, but not of GRK2, blocks this desensitization (105) . These results suggest that GRK3 specifically interacts with the G βγ combination released following α 2 -adrenergic receptor activation. The differential binding of specific G βγ isoforms to GRK2 and GRK3 would be predicted to be of primary importance in determining the substrate specificity of these enzymes.
The Lipid Dependence of GRKs
As discussed above, in the context of PIP 2 , specific experimental procedures have revealed the lipid dependence of GRKs. Lipids other than PIP 2 have also been shown to bind to and regulate GRK2. Negatively charged phospholipids such as phosphatidylserine (PS) promote GRK2-mediated phosphorylation of the β 2 AR and the m2 muscarinic acetylcholine receptor (95, 97, 107) . Several characteristics distinguish the enhanced GRK2 activity observed in the presence of PS from that observed in the presence of PIP 2 . These differences, summarized below, suggest that PS and PIP 2 represent members of two distinct classes of GRK2 lipid ligands and that their effects may be mediated by binding to distinct sites on GRK2.
PS and PIP 2 bind to GRK2 with very different affinities. At saturating G βγ (∼120 nM), concentrations of PIP 2 ranging from 1 to 20 mM dramatically stimulate GRK2-mediated GPCR phosphorylation (87, 97) . In marked contrast, the same concentrations of other negatively charged phospholipids have no effect on GRK2 activity (87, 97) . Effective stimulation of GRK2 activity by PS requires the presence of 10-to 20-fold higher concentrations of lipid. The difference in affinity of these two ligands for GRK2 is congruent with the difference in their estimated plasma membrane concentrations. Whereas the mole fraction percent for PS is estimated to be approximately 10% (108) , that for PIP 2 is estimated to be 1-3% (98) . Both lipids may thus represent physiologically relevant regulators of GRK2 activity.
PS, but not PIP 2 , directly activates GRK2. In contrast to PIP 2 , PS and other negatively charged phospholipids enhance GRK2-mediated phosphorylation of soluble peptide substrates (95, 97) . Consistent with this observation, PS, but not PIP 2 , appears to promote a comformational change in GRK2, as assessed by the lipid-promoted incorporation of a cross-linking agent into the enzyme (95) .
The PS-binding site of GRK2 has been mapped to the carboxyl-terminal domain (97) . In contrast to PIP 2 , however, the GRK2 PH domain has not been directly implicated as the site of PS interaction. Resolution of the crystal structures of several PH domains complexed to IP 3 indicates that the 4 and 5 phosphates of the inositol ring are critical determinants for binding (74, 76, 109) . PS lacks these determinants. This observation, coupled with the distinct GRK2-binding properties of PS and PIP 2 , suggests that PS may potentially bind to a carboxyl-terminal GRK2 site distinct from the PH domain.
Like GRK2, GRK5 is regulated by multiple lipid ligands. Two lipid-binding sites have been identified on GRK5: one in the carboxyl terminus and one in the amino terminus of this enzyme (110, 111) . The carboxyl-terminal lipidbinding site resides in the last 100 amino acids of GRK5 and displays no lipid specificity. Occupancy of this site stimulates GRK5 autophosphorylation and has been shown to promote GRK5-mediated phosphorylation of receptor substrates (110) . Although lipid binding stimulates autophosphorylation, the binding of lipid to GRK5 is apparently independent of the autophosphorylation status of GRK5 (110) . In contrast to the carboxyl-terminal site, the aminoterminal lipid-binding site exhibits a high degree of specificity for PIP 2 (111) . However, PIP 2 binding to this site does not affect GRK5 autophosphorylation (110) . When incorporated in PC vesicles, physiological concentrations of PIP 2 promote the vesicle association of GRK5 and restore the ability of this kinase to phosphorylate activated β 2 AR (111). As is the case for GRK2, PIP 2 has no direct effect on the catalytic activity of GRK5: GRK5-mediated phosphorylation of soluble peptide substrates is unaffected by the presence of this lipid. Autophosphorylation-deficient mutants of GRK5 reveal that the interaction with PIP 2 occurs independently of the autophosphorylation status of this enzyme. Mutation to alanine of six basic amino acid residues (Lys-22, 24, 26, 28, and Arg-23) in the amino terminus of GRK5 ablates PIP 2 -dependent GRK5 activity (111) .
The PIP 2 -binding site on GRK5 coincides with the GRK5-binding site for calcium/calmodulin (111, 112) , which inhibits the enzyme. The binding of PIP 2 and calcium/calmodulin to GRK5 would thus be predicted to be mutually exclusive. The sequence encompassing the PIP 2 /calmodulin-binding site is highly conserved among GRKs 4-6 and is divergent in GRK1, GRK2, and GRK3. Consistent with this observation, GRK4α, GRK5, and GRK6 all display PIP 2 -dependent β 2 AR phosphorylation (111) . Both GRK5 and GRK6 bind calcium/calmodulin (112) . Although it remains to be determined experimentally, it seems likely that this regulatory feature is also shared by GRK4.
Posttranslational Lipid Modifications of GRKs
Phosphorylation of activated GPCRs by GRKs necessitates the membrane localization of these enzymes. For three members of the GRK family (GRK1, GRK4, and GRK6), membrane localization is accomplished, at least in part, by the covalent attachment of lipids to their carboxyl-terminal domains. The amino acid sequence of GRK1 terminates in a CAAX motif (where C is cysteine, A is a small aliphatic residue, and X is an uncharged amino acid). For GRK1 this motif is CVLS, which directs the farnesylation (C15 isoprenylation) and carboxylmethylation of this protein (21) . The presence of the farnesyl group is essential for light-dependent membrane association of GRK1 (113) . A mutant unfarnesylated form of the kinase remains in the soluble fraction following light exposure and displays a reduced ability to phosphorylate rhodopsin. In contrast, a mutant kinase bearing a more hydrophobic geranylgeranyl (C20) isoprenoid moiety is constitutively associated with the membrane but phosphorylates rhodopsin at a rate comparable to wild-type (farnesylated) GRK1 (113) . The specific modification found in vivo, farnesylation, ensures that membrane association of GRK1 occurs only in the presence of its activated receptor substrate.
GRK4 and GRK6 are palmitoylated (40, 114) . Palmitoylation is the acylation of a protein with a 16-carbon saturated fatty acid (palmitic acid) through a thioester or an oxyester bond. In the most prevalent form of palmitoylation, cysteine residues are modified through a thioester bond. One or more of the cysteines located 12-17 amino acids from the carboxyl terminus represent the sites of palmitolylation in GRK6 (114) . By analogy with this enzyme, the probable site or sites of GRK4 palmitoylation are the carboxyl-terminal cysteine of GRK4 and a cysteine located 17 amino acids away from the carboxyl terminus of this enzyme (40) . Palmitoylated GRK4 and GRK6 are found exclusively associated with membranes (40, 114) . Palmitoylation is a reversible posttranslational modification. For several proteins, GPCR activation has been shown to be accompanied by a change in palmitoylation status. These proteins include certain GPCRs (115, 116) as well as nitric oxide synthetase (117) and the α subunits of heterotrimeric G proteins (118, 119) . For Gα s the loss of palmitic acid following GPCR activation is accompanied by the release of this protein from the membrane (120) . It remains to be determined whether the palmitoylation status, and thus potentially the subcellular localization, of GRK4 and GRK6 is regulated by agonist occupancy of GPCRs.
Regulation of GRKs by Protein Kinase C
GRK2 (a member of the GRK2 subfamily) and GRK5 (a member of the GRK4 subfamily) are phosphorylated in vitro and in intact cells by protein kinase C (PKC) (121) (122) (123) . The functional consequences of this phosphorylation event, however, are very different for these two enzymes. In vitro, PKC-mediated phosphorylation of GRK2 leads, albeit somewhat slowly, to the incorporation of between 0.5 and 0.9 moles P i /mole GRK2 and is accompanied by an approximately twofold activation of the enzyme toward activated rhodopsin (121, 122) . Notably, the PKC-dependent activation of GRK2 is specific to receptor substrates (as opposed to peptides), suggesting that PKC phosphorylation promotes membrane and/or receptor association of GRK2 rather than directly enhancing the catalytic activity of this enzyme (122) . In support of this hypothesis, direct activation of PKC by phorbol ester treatment of cells overexpressing GRK2 leads to a decrease in cytosolic GRK2 immunoreactivity, a result suggesting a PKC-dependent association of GRK2 with the plasma membrane (122) . In mononuclear leukocytes, GRK-mediated β 2 AR desensitization is potentiated in phorbol ester-treated cells, suggesting that PKC may play a physiologically relevant role in the regulation of GRK2 (121) . Although the PKC phosphorylation site or sites on GRK2 are unknown, a fusion protein encompassing the last 137 amino acids of GRK2 serves as a PKC substrate (122) . This fusion protein encompasses the PH domain of GRK2, and in this respect it is interesting to note that the PH domains of two other protein kinases [Bruton tyrosine kinase and RAC (related to A-and C-kinase)] bind PKC (124, 125) .
GRK5 serves as an excellent substrate for PKC in vitro; it is phosphorylated rapidly to a stoichiometry of approximately 2 moles P i /mole GRK5 (123) . In contrast to GRK2, GRK5 dramatically loses enzymatic activity-on both receptor and soluble substrates-consequent to phosphorylation by PKC (123) . The V max :K m ratio for GRK5-mediated phosphorylation of rhodopsin is decreased approximately 13-fold following PKC phosphorylation. Although the direct inhibition of catalytic activity appears to be the principal effect of PKC phosphorylation, phosphorylated GRK5 may also exhibit a reduced affinity for rhodopsin, as evidenced by a decreased ability to associate with rod outer-segment membranes but not lipid vesicles (123) . Mapping the two PKC phosphorylation sites on GRK5 reveals that both reside within the carboxylterminal 26 amino acids of GRK5 (123) at sites distinct from the sites of GRK5 autophosphorylation (110) .
Thus, members of two GRK subfamilies are regulated by PKC-mediated phosphorylation. The functional consequences of this phosphorylation event appear subfamily specific: GRK2 is activated, while GRK5 is inhibited. Alterations of PKC activity in a cellular setting would thus be predicted to regulate the cellular complement of active GRKs. Agonist occupancy of receptors coupled to G q/11 and phospholipase C leads to PKC activation. Desensitization of such receptors would thus be predicted to be mediated by GRK2 (a PKC-activated enzyme) rather than by GRK5 (an enzyme potently inhibited by PKC).
Olfactory Receptor Desensitization: A Novel Paradigm of GPCR Desensitization
Activation of odorant receptors in the cilia of olfactory neurons can lead to the generation of the second messengers cAMP and inositol-1,4,5-trisphosphate (IP 3 ) (126) . A characteristic feature of the signal transduction pathways in this tissue is the extent and rapidity of the desensitization process (126) (127) (128) . In a permeabilized rat olfactory cilia preparation, odorants induce an approximately fourfold increase in second-messenger (cAMP and IP 3 ) concentrations, which peak 25-50 ms after agonist exposure (9, 129, 130) . Olfactory receptor desensitization occurs extremely rapidly such that 100 ms after agonist exposure, second-messenger levels have returned to near basal values (9, 129, 130) .
Subtype-specific antibodies to GRK2 and GRK3 reveal that in marked contrast to most other tissues, olfactory epithelium expresses exclusively GRK3 (9, 129) . That GRK3 participates in olfactory receptor desensitization was demonstrated through the use of inhibitors of this enzyme: heparin (9); anti-GRK3 antibodies (9, 129) ; and a fusion protein encompassing the carboxyl terminus of the GRK3, a G βγ sequestrant (130) . Inhibition of GRK3 activity led to a complete loss of desensitization for both the cAMP and IP 3 signals. Interestingly, a similar pattern was observed when inhibitors of the second messengerdependent protein kinases were used (9) . Thus, inhibition of either GRK3 or PKA/PKC completely blocked olfactory receptor desensitization. This pattern of desensitization is in marked contrast to that observed with the β 2 AR, where GRK and PKA inhibitors partially and additively inhibit receptor desensitization (131) . The complete inhibition of olfactory receptor desensitization observed in the presence of either GRK3 inhibitors or the second messengerdependent kinase inhibitors suggests that in the olfactory epithelium, these enzymes act in a coordinated rather than an independent fashion. Notably, inhibition of PKA completely blocks both desensitization and receptor phosphorylation (9) . In contrast, inhibition of GRK3 completely blocks olfactory receptor desensitization but only partially blocks receptor phosphorylation. Because second-messenger phosphorylation events are operative in the presence of GRK inhibitors, these results suggest that PKA-mediated phosphorylation of olfactory receptors does not induce receptor desensitization. Several alternative regulatory mechanisms could explain the pattern of olfactory receptor desensitization. Second messenger-dependent kinases may directly phosphorylate and activate GRKs. Alternatively, PKA and PKC may phosphorylate and inactivate a GRK3 inhibitor.
In olfactory cilia, as described above, the PKA inhibitor peptide inhibits olfactory receptor desensitization. The PKA inhibitor peptide inhibits not only receptor desensitization but also translocation of GRK3 to the membrane (132) . Consistent with this observation, cAMP addition promotes the membrane localization of GRK3 (132) . These results suggest that an important effect of PKA activity may be to facilitate membrane, and thus receptor, targeting of GRK3. The ability of PKA to modulate GRK3 membrane targeting could be mediated by phosducin, a G βγ -binding PKA substrate found in olfactory cilia. Once phosphorylated by PKA, phosducin loses its affinity for G βγ , which could then recruit GRK3 to the odorant-activated receptors (133) (134) (135) . Whether termination of the odorant-induced generation of IP 3 is controlled by a similar cascade is unclear, because PKC-mediated phosphorylation of phosducin has not been demonstrated. Notably, however, PKC has been shown to phosphorylate and activate GRK2 in vitro (121, 122) . If PKC similarly regulates GRK3, then for receptors coupled to IP 3 generation, the specific desensitization pattern observed in olfactory cilia may be explained by the PKC-mediated direct activation of this enzyme.
Regulation of GRKs by Ca 2+ -Binding Proteins
Many Ca 2+ -sensing transducers are members of the EF hand superfamily of Ca 2+ -binding proteins (135a). Two members of this superfamily (recoverin and calmodulin) bind to and inhibit GRKs (112, (136) (137) (138) . Recoverin specifically inhibits GRK1 activity (IC 50 ∼ 2 µM) (136). In contrast, calmodulin inhibits GRK2, GRK5, and GRK6 (112, 137, 138) . Although not directly assessed, GRK3 and GRK4 are also presumed to represent calmodulin targets by virtue of their similarities to GRKs 2 and 5, respectively. Calmodulin inhibition of GRKs exhibits a selectivity for GRK5 (IC 50 ∼ 50 nM) > GRK6 GRK2 (IC 50 ∼ 2 µM), with inhibition of GRK1 activity observed only at supraphysiological concentrations of calmodulin (112, 137, 138 -dependent fashion, and it does so more potently in its myristoylated form (136) . Ca 2+ -complexed, myristoylated recoverin is membrane associated (141-143) . Similarly, the recoverin/GRK1 complex would be predicted to be membrane localized but inactive against receptor substrates. Recoverin would thus appear to inhibit GRK1 activity by preventing the interaction between this enzyme and activated photolysed rhodopsin.
In addition to potentiating the inhibitory effect of recoverin on GRK1, the N-myristoyl moiety of recoverin also confers cooperativity to the Ca 2+ -dependent inhibition of rhodopsin phosphorylation (136, 144) . Recoverin-mediated inhibition of GRK1 is thus extremely sensitive to Ca 2+ across a narrow range of concentrations (136, 144) . In the vertebrate photoreceptor system, Ca 2+ levels are high in the dark and drop following illumination (145) . Thus when rhodopsin is in its inactive state, GRK1 would be predicted to be complexed to recoverin, membrane associated, and inactive. Following rhodopsin activation, a decrease in intracellular Ca 2+ would be accompanied by the release of GRK1 from recoverin. The release of uninhibited GRK1 in close proximity to its activated receptor substrate may facilitate rapid rhodopsin phosphorylation and desensitization. Although this model is attractive, the inhibitory effects of recoverin in vitro require Ca 2+ concentrations significantly higher than the bulk intracellular free Ca 2+ levels in vertebrate photoreceptors (200-600 nM in the dark) (145) . What accounts for this apparent discrepancy? One explanation is that recoverin may function in a local environment; that is, close to the membrane, where Ca 2+ concentrations may be significantly higher than the concentration of the bulk free Ca 2+ . Alternatively, additional proteins absent from the reconstituted systems used in vitro may be required for recoverin to operate in the physiological range of free Ca 2+ concentrations.
CALMODULIN-MEDIATED INHIBITION OF GRK2 AND GRK5
As with recoverinmediated inhibition of GRK1, calmodulin binds directly, though with different affinities, to both GRK2 (IC 50 ∼ 2 µM) and GRK5 (IC 50 ∼ 50 nM) to inhibit the interaction of these enzymes with their agonist-occupied receptor substrates (112, 137, 138) . Inhibiting the interaction of the GRKs with activated receptor substrates would be predicted to inhibit GPCR-mediated allosteric activation of these enzymes. Indeed, for GRK2 or GRK2/G βγ , calmodulin in the presence of Ca 2+ inhibits the agonist-dependent stimulation of peptide phosphorylation observed in the presence of a nonphosphorylatable mutant of the m2 muscarinic acetylcholine receptor (138). GRK5's calmodulin binding, in addition to inhibiting the interaction of GRK5 with GPCRs, inhibits the association of this kinase with lipid vesicles (112). Calmodulin is not modified by fatty acylation. The GRK5/calmodulin complex would thus be predicted to differ from the GRK1/recoverin complex in that it would not be membrane associated.
The binding site for calmodulin has been mapped on GRK5 and shown to reside within the amino terminus of the enzyme (residues 20-39) (112). This region also constitutes the PIP 2 -binding site of GRK5 (111), an observation that may explain the inhibition of GRK5 binding to lipid vesicles observed in the presence of calmodulin (112) . The calmodulin-binding site of GRK5 displays properties characteristic of an amphiphilic helix and is thus similar to calmodulin-binding sites identified in other proteins (146) . The peptide sequence surrounding the PIP 2 /calmodulin-binding site is highly conserved between members of the GRK4 subfamily, but is divergent in GRK1 and GRK2. This observation suggests (a) that calmodulin binding, like PIP 2 binding, is likely to be a property shared by all the members of the GRK4 subfamily and (b) that GRK2 contains a calmodulin-binding site structurally distinct from that mapped in GRK5. Structurally distinct calmodulin-binding domains would explain the very different affinities of GRK2 and GRK5 for calmodulin. GRK2 and GRK5 bind PIP 2 via structurally distinct domains, and an analogous situation may thus also exist for calmodulin.
Calmodulin binding to GRK5 has an additional effect that is likely to be specific to this enzyme: It promotes GRK5 autophosphorylation at sites distinct from those phosphorylated in the absence of this protein (112) . Although not primarily responsible for mediating calmodulin-dependent inhibition, Ca 2+ -stimulated autophosphorylation of GRK5 prevents the interaction between GRK5 and rhodopsin in the absence of calmodulin (112) . The GRK5 inhibitory effects of intracellular calcium transients might thus be prolonged by calmodulin-stimulated GRK5 autophosphorylation (112) . Interestingly, an inverse regulatory mechanism has been proposed for CaM-kinase II, an enzyme for which calmodulin binding and calmodulin-stimulated autophosphorylation activate rather than inhibit activity (147) .
GRK2-and GRK5-mediated desensitization of GPCRs would be predicted to be inhibited in the presence of Ca 2+ /calmodulin. The relatively low affinity of GRK2 for calmodulin suggests that inhibition of GRK2 would occur only at locations specifically enriched in calmodulin. One such locale is the brain, where concentrations of calmodulin are reported to range between 1 and 10 µM (147). GRK2 is particularly abundant at the synapse (4), and a calmodulin-dependent inhibition of GRK2 activity may be of physiological relevance under these conditions. Alternatively, an EF hand-binding protein distinct from calmodulin may represent the true physiological ligand for GRK2. This hypothesis is particularly attractive because a number of neuronal proteins highly homologous to recoverin, and capable of inhibiting GRK1 activity in vitro, have recently been identified (148) . Interestingly, one such protein, neuronal calcium sensor (NCS-1), can bind to and regulate a number of calmodulin targets (149) . It will be of interest to determine whether NCS-1 is also capable of regulating GRKs 2-6. The high affinity of GRK5 for calmodulin suggests that this regulatory mechanism may be operative in multiple cell types. Coupled with the inhibitory effect of PKC on GRK5 activity, the marked inhibition of GRK5 by calmodulin strongly suggests that this kinase is probably not involved in the phosphorylation and desensitization of G q/11 -and phospholipase-C-coupled receptors, such as the angiotensin II receptor, in vivo.
Regulatory Role of GRK Autophosphorylation
Of the six GRKs, only GRK1 and GRK5 undergo significant autophosphorylation (23, 24, 65, 110, 150) . GRK1 autophosphorylation occurs rapidly to a stoichiometry of approximately 3 moles P i /mole GRK1 (65, 150) . The autophosphorylation sites have been mapped to Ser-488 and Thr-489, with Ser-21 representing a minor autophosphorylation site (151) . Autophosphorylation of GRK1 does not affect the ability of this enzyme to bind to or phosphorylate rhodopsin (65, 150) . However, as compared to an autophosphorylationdeficient mutant of the kinase, the autophosphorylated form of GRK1 displays impaired binding to phosphorylated, light-activated rhodopsin (150) . GRK1 autophosphorylation has thus been proposed to play a role in facilitating dissociation of GRK1 from its receptor substrate following phosphorylation.
The effect of autophosphorylation on GRK5 function appears distinct from that on GRK1. Autophosphorylation of GRK5 is stimulated nonspecifically by lipids to a stoichiometry of approximately 2 moles P i /mole GRK5 (110) . Comparison of the GRK1 and GRK5 sequences reveals that the two major autophosphorylation sites in GRK1 are conserved in GRK5 (residues Ser-484 and Thr-485). Mutation of these sites to alanine produces a form of GRK5 that does not autophosphorylate (110) . Compared with wild-type GRK5, this autophosphorylation mutant displays a dramatically impaired ability to phosphorylate membrane-incorporated receptor substrates (110) . However, the catalytic activity of GRK5 seems minimally affected by autophosphorylation, because GRK5-mediated phosphorylation of soluble peptide substrates is only modestly stimulated (approximately twofold) by autophosphorylation (110) . Furthermore, autophosphorylation does not affect the lipid binding of GRK5, because an autophosphorylation-deficient mutant of GRK5 can inhibit phospholipidstimulated autophosphorylation of the native enzyme (110) . Together, these observations suggest that autophosphorylation specifically promotes the interaction of GRK5 with its activated receptor substrates, thereby facilitating GPCR-mediated allosteric activation of this enzyme.
The GRK5 autophosphorylation stimulated by calcium/calmodulin occurs at sites distinct from Ser-484 and Thr-485 (112) and impairs rather that facilitates GRK5/receptor binding. Thus, the nature of the ligand binding to GRK5-phospholipid or calcium/calmodulin-determines which sites become autophosphorylated. This autophosphorylation in turn provides another level of regulation for the interaction between GRK5 and its receptor substrates.
Regulation of GRK Activity by Other Targeting Proteins
Significant amounts of GRK2 have been shown to be specifically associated with microsomal membranes (152, 153) . This GRK2/microsomal membrane interaction is reversible, of high affinity (nanomolar), and, as judged by protease sensitivity, mediated via a protein/protein interaction (152) . GRK2 binding to microsomal membranes is blocked upon addition of a GST-fusion protein containing residues from the amino (residues 50-145) but not the carboxyl terminus of the kinase (153) . Although membranes containing the GRK2-binding protein inhibit GRK2-mediated rhodopsin phosphorylation, this inhibition is relieved in the presence of activators of the heterotrimeric G proteins (153) . The binding of GRK2 to the inhibitory GRK2-binding protein of microsomal membranes provides a mechanism for regulating, in a GTP-dependent fashion, the activity of membrane-associated GRK2. These findings raise the possibility that additional, unidentified proteins direct GRK2, as well as other members of the GRK family, to distinct subcellular compartments and thus potentially to different receptor substrates.
CELLULAR STUDIES
From the time they led to the discovery of GRK2 (15), cultured cells have served as fundamental tools for investigations of GRK function. These investigations can be categorized broadly as studies that (a) evaluate the contribution of GRK action, among other mechanisms, to the desensitization of a particular receptor; (b) investigate the kinetics of GRK-initiated desensitization; (c) define GRK subcellular localization; (d ) assay factors affecting GRK expression or activity; and (e) evaluate candidate receptor substrates. Although the preponderance of these studies employ immortalized cell lines, several of the conclusions derived from these cell lines have been corroborated by studies performed in primary cultures of cells (105, (154) (155) (156) (157) (158) , the constituents of which more closely model in vivo conditions. In immortalized cell lines (159) (160) (161) (162) as well as in primaryculture models (9, 105, 129, 163, 164) , there may be considerable cell typespecific variation in relative and even absolute GRK expression. For certain receptors, this cell type-specific GRK expression may affect susceptibility to GRK-mediated phosphorylation and desensitization (165) .
The Contribution of GRKs to Homologous Desensitization
To evaluate the importance of GRK action in cellular systems, various methods of inhibiting GRK action in cells have been devised. In permeabilized human epidermoid carcinoma A431 cells, the GRK-selective inhibitor heparin (24, 54, 55, 166) has been used to estimate that GRK activity contributes ∼60% of the agonist-induced β 2 AR phosphorylation and desensitization observed (the remainder was attributed to cAMP-dependent protein kinase) (167) . In the same permeabilized cell system, inhibiting GRK2 with a peptide corresponding to the first intracellular loop of the β 2 AR suggested that 52% of agonist-induced β 2 AR desensitization derived from GRK action (64) . In consonance with these results, when A431 cells were treated with antisense oligodeoxynucleotides to inhibit GRK2 synthesis, the amount of β 2 AR desensitization attributed to GRK activity was also ∼50% (160). For β 2 AR (160) and H 2 -histamine receptor (168) desensitization in other cell lines, the antisense approach has shown the relative contribution of GRK2 to range from 0% to 100%, an observation that attests to cell type-specific variability in desensitization mechanisms. In permeabilized rabbit cardiac myocytes, GRK-specific antibodies were used to demonstrate that agonist-induced β 2 AR phosphorylation is totally GRK2-dependent (158) . In transfected cells, the dominant negative (K220R or equivalent) mutant of GRK2 (169) has been used to inhibit specifically GRK-mediated agonist-induced phosphorylation and/or desensitization of several receptors (60) (61) (62) (170) (171) (172) (173) , with results varying from 40% to 60% inhibition of phosphorylation and 50% to 100% inhibition of desensitization (61, 62, 171) .
The relative importance of GRK-initiated receptor desensitization has also been addressed with the use of mutant receptors in transfected cells. After the β 2 AR Ser and Thr residues phosphorylated by purified GRK2 were localized to the cytoplasmic tail of the receptor (174), mutations of 11 Ser and Thr residues in this region to Ala or Gly yielded a receptor that sustained only 50% as much agonist-induced phosphorylation and desensitization as the wild-type β 2 AR (37). The observation of a reduction in agonist-induced phosphorylation and/or homologous desensitization consequent to mutating presumptive GRK phosphorylation sites has subsequently been used to implicate GRKs in the regulation of many receptors (50, (175) (176) (177) (178) . This strategy should be used cautiously, however, because results obtained with site-directed mutagenesis can sometimes prove misleading, as the prototypical β 2 AR has illustrated.
A mutant β 2 AR resistant to homologous desensitization and agonist-induced phosphorylation was created by mutating to Ala or Gly 4 of the 11 cytoplasmic tail Ser/Thr residues described above: Ser-355, Ser-356, Thr-360, and Ser-364 (179) . However, subsequent amino acid sequencing of GRK2-phosphorylated β 2 AR peptides (38) demonstrated that the only β 2 AR Ser and Thr residues phosphorylated by GRK2 or GRK5 lie in the cytoplasmic tail C-terminal to the Ser-364 mutated in the study cited above.
The Kinetics of GRK-Mediated Events
The rapid intracellular kinetics of GRK-initiated desensitization have been studied best in two permeabilized cell systems: (a) A431 cells (180) and (b) dendrites of rat olfactory neurons (9, 129) . Representative of somatic cells, A431 cells demonstrated GRK-mediated β 2 AR phosphorylation and desensitization to transpire with a t 1/2 of ∼15 sec. Representative of more specialized neuronal cells, olfactory dendrites demonstrated GRK3-mediated odorant receptor desensitization to transpire considerably more rapidly-within 200 ms. Because GRKs 2 and 3 have been shown to localize to receptor-rich pre-and postsynaptic densities in the rat central nervous system (4), it is not surprising that GRKmediated receptor regulation proceeds most rapidly in neuronal cells (105) .
Subcellular Localization
The subcellular localization of GRKs is of interest primarily because the receptor substrates for these enzymes are integral membrane proteins. From studies of unstimulated, disrupted cells, it seems that GRKs 4-6 are tightly adherent to cell membranes (24, 40, 114) , whereas GRKs 1-3 are primarily cytosolic and translocate to the membrane fraction of the disrupted cells when the cells are stimulated with an appropriate receptor agonist (81, 130, 159, 181, 182) . The agonist-dependent GRK2 translocation from cytosol to plasma membrane can be seen as well in whole cells, with confocal microscopy (182) . It is also possible, however, to demonstrate GRK2 in the plasma membrane, cytosolic, and microsomal membrane compartments of whole cells with immunofluorescence or density-gradient centrifugation (152) .
Factors Affecting GRK Expression or Activity
The factors affecting cellular expression and activity of GRKs are only beginning to manifest themselves in experimental systems. Perhaps surprisingly, elevating cellular cAMP levels appears to have no effect on GRK2 expression (30) and appears to decrease GRK5 expression in rat thyroid cells (183) . Despite these results in cultured cells, β-adrenergic antagonist treatment of swine has been shown to decrease assayable GRK activity in ventricular myocardium (184) . Chronic activation of protein kinase C (PKC) with phorbol ester in lymphocytes (157) appears to up-regulate GRK2 expression two-to threefold. Interestingly, short-term PKC activation appears to increase the activity of GRK2 in these same cells, as judged by β 2 AR desensitization (121) . Under somewhat different conditions, phorbol ester can also apparently up-regulate GRK6 and down-regulate GRK2 in lymphocytes (161) . Polyclonal activation of human lymphocytes with phytohemagglutinin (157, 161) or interleukin-2 (161) has also been shown to up-regulate GRK2 and GRK6 expression. Whereas a twofold up-regulation of GRK6 accompanies myeloid differentiation of HL-60 leukemia cells, a twofold up-regulation of GRK2 accompanies monocytic differentiation of these same cells (161) . Undoubtedly, many of the factors that modulate the cellular expression of GRKs will, like the cellular expression of GRKs, prove cell type-specific.
RECEPTOR SUBSTRATES OF GRKS
Approaches Employed to Identify GRK Substrates
To portray the continually enlarging cadre of receptors that appear to be regulated by a GRK mechanism, we have created a data summary in Table 1 . Attempts to determine whether a particular G protein-coupled receptor is or can be phosphorylated by a particular GRK have evolved in several directions, and Table 1 seeks to accommodate considerable diversity among the experimental data. Below, we discuss the types and quality of evidence used to implicate GRKs in homologous receptor desensitization.
Because agonist-induced receptor phosphorylation constitutes the hallmark of GRK activity, direct studies of receptor phosphorylation have provided the most straightforward and convincing evidence for identifying GRK substrates. Studies of homologous receptor desensitization, though more difficult to interpret than phosphorylation studies, have also provided strong evidence for identifying GRK substrates. The combination of phosphorylation and desensitization data militates most cogently for the identity of a particular GRK substrate.
To discern that a particular GRK can phosphorylate a particular receptor, the earliest phosphorylation assays involved purified kinases and purified receptors reconstituted in phospholipid vesicles, or rod outer segments. The demonstration of desensitization in these assays has utilized heterotrimeric G proteins, in agonist-dependent GTPase assays with (7, 8, 29, 185, 186) or without (99, (186) (187) (188) (189) ) the addition of arrestin or β-arrestin proteins. Because many G protein-coupled receptors lose ligand-binding capacity in detergent solution (190) , however, this approach has been limited to a small number of model receptors. Moreover, because phospholipids (95, 97, 110, 111) and G proteins (83, 88) are important for GRK-mediated receptor phosphorylation, other experimental systems seemed desirable. Accordingly, GRK-mediated receptor Notes: GRK, G protein-coupled receptor kinase; P, receptor phosphorylation mediated by a specific GRK; S, desensitization or inhibition of receptor signaling mediated by a specific GRK, in a time course consistent with GRK action; IP, immunoprecipitation of receptors phosphorylated by a cellular kinase(s) resistant to inhibitors of second messenger-dependent kinases; IP DN phosphorylation was demonstrated with membranes from cells expressing high receptor numbers, either with highly purified plasma membrane preparations (96, 197) or with crude cell membranes subjected to receptor immunoprecipitation subsequent to phosphorylation (192) . To evaluate GRK-mediated phosphorylation in a cellular milieu, several laboratories (60) (61) (62) (170) (171) (172) (173) have used cells transfected with receptors and a dominant negative (K220R or equivalent) mutant of GRK2, which specifically (60), but incompletely (169), inhibits GRK activity. Inhibition of agonist-induced receptor phosphorylation by this dominant negative GRK2, assessed by receptor immunoprecipitation, has been interpreted to imply that a cellular GRK not only can, but also does, phosphorylate the receptor. To attribute activity on certain receptors to a particular GRK, permeabilized cells have been treated with either GRK-specific antibodies (9, 158) or GRK2-or GRK3-specific antagonist peptides (105, 130) to inhibit agonist-induced receptor phosphorylation (9, 130, 158) and desensitization (9, 105, 130, 158 ). Yet another method employed to attribute intracellular agonist-induced receptor phosphorylation to a particular GRK has involved cells transfected with both receptor and individual GRK cDNAs. In these assays, transfected cells express levels of GRK protein manyfold higher than endogenous cellular levels. Augmentation of agonist-induced receptor phosphorylation in cells overexpressing a GRK has therefore been interpreted as evidence for that GRK's activity, an inference confirmed with several receptors in assays using purified proteins (17, 60, 172, 193, 194) . Negative results from these assays may be difficult to interpret, however, because the receptor phosphorylation observed derives from the activity of both transfected and endogenous cellular GRKs (usually GRK2).
Agonist-induced receptor phosphorylation studies in intact cells have also generated data that could be classified as evidence suggestive of GRK activity. These receptor immunoprecipitation studies have demonstrated agonistinduced receptor phosphorylation transpiring within the rapid time course characteristic of GRK-mediated processes and furthermore demonstrated the receptor phosphorylation to be resistant to inhibitors of second messengerdependent protein kinases (60-62, 156, 167, 171, 177, 178, 192, 200, 201, 206, 209, 211) . A last category of suggestive phosphorylation evidence comprises early experiments in which cells were stimulated with specific agonists and then disrupted and separated into membrane and cytosolic fractions, which were assayed for GRK activity. If GRK activity translocated from the cytosolic to the membrane fraction of the cell on agonist stimulation, the receptor for that agonist was inferred to be a GRK substrate (81, 159, 212) . We have omitted data based on only GRK-mediated phosphorylation of receptor-derived peptide fragments (52, 176) , because peptide phosphorylation studies involve no allosteric activation of the GRK by agonist-occupied receptors.
Cellular signaling studies roughly parallel the receptor phosphorylation assays. The inhibition of homologous receptor desensitization in permeabilized or intact cells has provided evidence for GRK substrates. This evidence ranges in quality from suggestive, with heparin (9, 167, 176, 196, 205) , to convincing, with specific antibodies (9, 158) , peptides (105, 130) , or antisense oligonucleotides or mRNAs (160, 168, 215) . The ability of dominant negative GRK2 to attenuate desensitization assessed in membrane assays has accorded well with phosphorylation studies employing this construct (61, 62). Suppression of agonist-evoked second-messenger responses in intact cells transfected with GRKs, on the other hand, has provided data discordant with phosphorylation studies (61, 62, 173) . The suppression of receptor signaling by a transfected GRK in these overexpression systems appears to correlate not with GRKmediated receptor phosphorylation but with agonist-induced binding of the overexpressed GRK to the activated receptor, as assessed by coimmunoprecipitation (62) .
Substrate Specificity
Increasingly, it seems that the vast majority of G protein-coupled receptors will prove to be substrates for GRKs. Because the preponderance of mammalian cells and tissues tested thus far express more than one GRK, divining which GRKs regulate which receptors has proved daunting. Only with GRK1 and GRK4, with severely restricted cell-type expression, can we confidently infer-or reasonably speculate-about in vivo receptor substrates. GRK1, restricted primarily to retinal photoreceptor cells (21) , certainly phosphorylates rhodopsin in vivo, and GRK4, restricted to the spermatogonia cell lineage (42) , may prove to phosphorylate the olfactory-like sperm receptors (216) in vivo. With the surfeit of receptors and relative scarcity of GRKs, it seems overwhelmingly likely that the other GRKs each regulate innumerable receptors, probably in a cell type-specific manner. That is, regulation of a given receptor in a particular cell will be determined not only by which GRK or GRKs are expressed in that cell, but also by the relative and absolute expression levels of each GRK in that cell (165) . The inhibition of specific GRKs in cellular systems, described above (9, 129, 130, 158, 160, 168, 215) , has offered valuable insights into cell type-specific GRK substrate specificity.
Intimations of true enzymatic GRK substrate specificity have emanated from phosphorylation assays with purified proteins (17, 54, 96, 197, 198) and peptides (53) (54) (55) . By examining the kinetics and stoichiometry of receptor phosphorylation, these studies suggest that certain receptors are not equally well phosphorylated by each of the purified GRKs (54, 96, 197, 198) . In interpreting these studies, however, we must consider the possibilities that the absence of GRK isoform activators or the presence of inadvertantly copurified GRK isoform inhibitors (207) have affected the results.
Finally, let us consider GRK substrate specificity more globally, by asking what G protein-coupled receptors, subjected to the assays described above, have proved refractory to GRK-mediated phosphorylation. To our knowledge, there are only two: the β 3 -adrenergic (217) and the α 2c -adrenergic (194, 195) receptors. Neither of these receptors appears to undergo agonist-induced desensitization, and neither appears susceptible to GRK2-mediated phosphorylation in the sort of intact cell systems described above. These receptors therefore provide valuable negative controls supporting the validity of the approaches taken to implicate GRKs in the homologous desensitization of other GPCRs.
STUDIES WITH GENETICALLY ALTERED MICE
Most information about GRKs has been obtained from in vitro studies, many of which utilized purified and recombinant molecules. Recently, however, a number of papers have been published that investigate the roles of kinases in living animals. These studies, which have utilized both transgenic and knockout mice, have both confirmed predictions from earlier in vitro work and provided a number of interesting surprises. Most of the data pertain to the roles of GRKs in cardiac function and development (218, 219) .
Transgenic Animals
Transgenic mice were created with cardiac-specific overexpression of either GRK2 or a GRK2 antagonist, comprising the carboxy terminal 195-amino acid segment of GRK2 (residues 495-689) (220) previously shown to function as a G βγ -sequestering protein in vitro (84) . In each case the transgene was driven by the murine alpha myosin heavy-chain promoter (221) . Animals overexpressing GRK2 showed attenuation of isoproterenol-stimulated left ventricular contractility in vivo, reduced sarcolemmal adenylyl cyclase activity, and diminished functional coupling of β-adrenergic receptors (220) . Conversely, mice expressing the GRK2 inhibitor displayed enhanced cardiac contractility in vivo with or without isoproterenol (220) . These studies were the first to demonstrate the ability of a GRK to desensitize G protein-coupled receptors in vivo. Moreover, they demonstrated the important role of GRK2 in modulating in vivo myocardial function, even in the absence of exogenous catecholamines. Consonant with these results, isolated cardiac myocytes from these transgenic mice demonstrate perturbations in contractility similar to those observed in vivo (222) .
GRK5 is also abundantly expressed in the mammalian heart (23, 24) . A transgenic mouse overexpressing GRK5 in the heart also showed marked β-adrenergic receptor desensitization as judged by in vivo isoproterenol-stimulated contractility (223) . The dampening of catecholamine-stimulated contractility was even more striking than that observed in the GRK2-overexpressing animals; however, the relative overexpression of GRK5 was also much greater than that of GRK2. Interestingly, whereas angiotensin II-stimulated contractility was unaffected in these GRK5-overexpressing mice, it was blunted in the GRK2-overexpressing mice (223) . Because activation of angiotensin II type 1 receptors increases intracellular calcium, the consequent activation of calmodulin may inhibit myocardial GRK5 action more than it does GRK2 action (112, 137) and explain the apparent GRK specificity. These data suggest that myocardial overexpression of GRK5 results in selective uncoupling of G protein-coupled receptors and demonstrate that receptor specificity of GRKs may be important in determining physiological phenotype.
Knockout Animals
When the mouse gene for GRK2 was disrupted by homologous recombination, no homozygous embryos survived beyond gestational day 15.5 (224) . Prior to this time, −/− embryos displayed pronounced hypoplasia of the ventricular myocardium essentially identical to the thin myocardium syndrome observed on gene inactivation of several transcription factors (RXRα, N-myc, TEF-1, WT-1) (225) . Embryonic death of the −/− embryos appears to be due to heart failure, as cardiac ejection fraction is markedly reduced (224) . These results, along with the virtual absence of endogenous GRK activity in GRK2 −/− whole embryos, demonstrate that GRK2 is the predominant GRK in early embryogenesis and that it plays a fundamental role in cardiac development. The nature of this role remains obscure. The data, however, hint at an as yet unappreciated interaction between GRK2 and transcription factor pathways.
Whereas GRK2−/− embryos all die in utero, +/− embryos not only survive but also appear normal with regard to gross morphology, growth, and development. As adults they have a ∼50% reduction in tissue (cardiac) GRK2 levels (224) . Interestingly, this 50% reduction in cardiac GRK2 levels is associated with significant increases in in vivo contractile responses to isoproterenol (H Rockman, W Koch, S Akhter, RJ Lefkowitz, MG Caron, submitted manuscript). When GRK2 +/− animals are bred with animals overexpressing the GRK2 inhibitor peptide, the doubly transgenic animals show even greater contractility enhancement and a further lowering of myocardial G βγ -stimulated GRK activity to ∼25% of wild-type animals (H Rockman, W Koch, S Akhter, RJ Lefkowitz, MG Caron, submitted manuscript). Similar alterations in contractility could be observed in ventricular myocytes isolated from these various animal lines. These data further strengthen the notion that cardiac function in vivo is strongly modulated by the levels of GRK2 activity.
In contrast to the embryonic lethality of the GRK2 gene knockout, deletion of the GRK3 gene in mice allows for normal embryonic and postnatal development (227) . GRK3 is known to be highly expressed in olfactory epithelium and to function in desensitization of olfactory second-messenger signaling (9, 129, 130) . In accordance with these observations, olfactory cilia preparations derived from GRK3-deficient mice lack the fast agonist-induced desensitization normally seen after odorant stimulation (227) . In addition, olfactory cilia (but not other tissues) of these mice demonstrate a dampening of the G protein-adenylyl cyclase system that may compensate for the desensitization defect observed. The findings confirm the requirement of GRK3 for odorantinduced desensitization of cAMP responses.
POTENTIAL INVOLVEMENT OF GRKS IN HUMAN DISEASE
Because the array of receptors regulated by GRKs (Table 1 ) affect so many vital functions, it seems likely that disorders of GRK-mediated regulation would contribute to, if not engender, disease. Alternatively, alterations in GRK expression and activity might help to compensate for excessive stimulation of certain receptor signaling systems. These possibilities have manifested themselves thus far in five disease areas.
Opiate addiction:
In rats treated chronically with morphine, GRK2 levels increased in the locus coeruleus. This increased GRK2 activity (perhaps involved in phosphorylating the µ-opioid receptor) may both compensate for hyperstimulation of central nervous system opioid receptors and contribute to the problem of opiate tolerance (228).
Retinitis pigmentosa:
Failure to desensitize rhodopsin signaling leads to photoreceptor cell death (3, 10) , as is observed in retinitis pigmentosa. This disease has been associated with many mutations in rhodopsin, including several in the cytoplasmic tail domain (229, 230) , where GRK1-mediated phosphorylation leads to termination of receptor signaling (47).
3. Hypertension: Elevated GRK2 levels have recently been demonstrated in peripheral blood lymphocytes of a subgroup of hypertensive patients with impaired β 2 AR-mediated vasodilation (231) . Because β 2 AR regulation in lymphocytes parallels that observed in vascular smooth muscle cells in hypertensive subjects, the GRK2 up-regulation seen in these lymphocytes may underlie the attenuation of β 2 AR-mediated vasodilation in the hypertensive subjects studied (231).
Myocardial ischemia:
Up-regulation of GRK2 manifests itself in rat heart muscle deprived of oxygen for prolonged periods. This GRK2 up-regulation correlates temporally with diminishing responsiveness of β-adrenergic receptor-stimulated cyclase activity (232).
Chronic heart failure:
A reproducible constellation of abnormalities in myocardial β-adrenergic receptor signaling has been observed both in material from human hearts (233) and in various animal models of heart failure (234) . These include decreased contractile and adenylyl cyclase responses to β-agonists, decreased numbers and G s coupling of myocardial β 1 -adrenergic receptors, and elevated levels of myocardial GRK activity (presumably GRK2 but possibly including GRK5) (233, (235) (236) (237) . The extent of GRK2 up-regulation observed in human chronic heart failure approximates that achieved in the GRK2-overexpressing transgenic mice described above (220, 236) . As we have seen, a growing body of data appears to indicate that myocardial GRK2 levels correlate directly with and may significantly control myocardial contractility. These findings have suggested a testable hypothesis: that lowering myocardial GRK2 levels might offer a therapeutic strategy for improving myocardial contractile performance in the setting of the failing heart (238) .
This hypothesis has been tested only in isolated cardiac myocytes from rabbits with pacing-induced congestive heart failure, characterized by a diminished myocardial maximum dP/dT (239) . The pacing-induced heart failure was associated with reduction of the number of β-adrenergic receptors and increases in membrane GRK2 activity in the isolated ventricular myocytes (239) . Adenoviral-mediated gene transfer of the GRK2 carboxy terminus peptide inhibitor into these failing myocytes led to the restoration of βAR signaling (239), much as this GRK2 inhibitor enhanced isoproterenol-stimulated cAMP in ventricular myocytes from normal rabbits (238) . These in vitro studies raise the possibility that successful gene transfer or chemical inhibitors of GRK2 might have therapeutic utility in the setting of human heart failure.
FUTURE DIRECTIONS AND PERSPECTIVES
The initial observations that phosphorylation of activated rhodopsin or β 2 AR initiates receptor desensitization led to the identification of the GRK family of serine/threonine kinases, currently comprising six members. In the years since their discovery, the GRKs have been shown to phosphorylate and initiate desensitization of an impressive array of GPCR substrates (see Table 1 ). The critical importance of GRKs in regulating GPCR function has been revealed by a combination of studies in vitro using purified proteins, investigations of GPCR phosphorylation and desensitization in cellular systems, and, more recently, examination of the effects of deletion or overexpression of GRK genes in intact animals. Furthermore, burgeoning investigations portray a family of enzymes exquisitely and differentially regulated by a variety of different signaling molecules. Thus, for GRKs, the interaction with GPCR substrates; posttranslational modifications; and the binding of distinct structural domains to G βγ , calmodulin, and a variety of different lipids serve to link GPCR activation inextricably to GRK-initiated desensitization.
Recent data hint at further, hitherto unsuspected roles for these enzymes and for GPCR phosphorylation in general. In addition to receptor desensitization and attenuation of cellular signaling, GRKs and cAMP-dependent protein kinase (PKA) appear to play an additional role: that of signal switching.
The β 2 AR, like many GPCRs, couples to several different classes of G proteins (240-243). While many β 2 AR processes occur consequent to β 2 AR/G s coupling and activation of adenylyl cyclase (37, 244) , other β 2 AR-stimulated processes occur consequent to G i activation (240, 242). β 2 AR-mediated G i activation has recently been shown to depend on the phosphorylation status of the receptor (245) . PKA-mediated phosphorylation of the β 2 AR appears to switch the coupling of this receptor from G s to G i (245) . Thus, PKAmediated β 2 AR phosphorylation attenuates β 2 AR-stimulated cAMP production both by inhibiting the β 2 AR's coupling to G s and by promoting its coupling to G i .
In many systems, the G βγ subunits of G i can initiate mitogen-activated protein (MAP) kinase cascades (246) . The β 2 AR has also been shown to initiate this effector pathway (245) , but in a manner that is dependent on phosphorylation of the β 2 AR not only by PKA but also by a GRK (247) . Whereas PKAmediated receptor phosphorylation facilitates coupling to G i , GRK-mediated receptor phosphorylation facilitates the receptor's binding to a β-arrestin isoform. This binding event both uncouples the receptor from G proteins and targets the receptor to clathrin-coated pits, where receptor endocytosis begins. β 2 AR endocytosis appears essential for the activation of MAP kinase by this receptor (247) . β 2 AR-mediated MAP kinase activation is thus intimately dependent on the phosphorylation status of the receptor. These observations suggest a new paradigm for GRK-and PKA-mediated phosphorylation of GPCRs in which these enzymes, rather than acting merely as signal attenuators, act as signal switches determining the nature of the signal transduction cascade initiated by a single receptor.
In addition to terminating and switching signal transduction pathways via receptor phosphorylation, GRKs may participate directly in GPCR-mediated signal transduction. The interaction of GRKs with activated receptor substrates leads to the allosteric activation of these enzymes, dramatically enhancing peptide substrate phosphorylation. GRKs thus represent enzymes that are specifically activated following GPCR occupancy and may participate in signal transduction cascades by phosphorylating non-GPCR substrates. This model of GRK action is particularly attractive in light of the recent observation that tubulin, the building block of microtubules, serves as an excellent substrate for GRK2 (248) . The kinetic parameters of tubulin phosphorylation are similar to those of agonist-occupied β 2 AR, and GRK2 associates with microtubules in intact cells. Furthermore, in cells, tubulin phosphorylation is potentiated following GPCR activation (248) . It is tempting to speculate whether GRK2-mediated tubulin phosphorylation mediates, at least in part, the reported effects of GPCRs on the cytoskeleton (249, 250) . The search for additional nonreceptor GRK substrates is in progress.
The binding of kinases to specific proteins with discrete subcellular distributions provides an attractive mechanism for regulating their activity and specificity. Such targeting proteins have been identified for PKA and PKC: A-kinase anchoring proteins (AKAPs) (251) and receptors for activated PKC (RACKs) (252), respectively. That similar proteins exist for GRKs is supported by the observation that GRK2 binds with high affinity to a microsomal protein, dubbed protein X (152, 153) . When bound to protein X, GRK2 is inhibited, but activators of heterotrimeric G proteins (GTPγ S or A1F − 4 ) can relieve this inhibition, even though protein X does not appear to be a heterotrimeric G protein (153) . In this respect it is interesting to note that the GRKs contain within their amino termini a region that is homologous to a family of proteins termed regulators of G protein signaling (RGS) (253) . RGS proteins bind to the α subunits of activated G proteins to facilitate GTP hydrolysis (254, 255) . Could protein X be homologous to G protein α subunits? The characterization of protein X and the potential identification of other GRK-targeting proteins are likely to provide considerable insight into the mechanisms of regulation as well as the substrate specificity of GRKs.
Most of the studies utilizing GRKs have centered on their role as mediators of GPCR desensitization. Recent evidence, however, points to a role for these enzymes as propagators or initiators of signal transduction. The second decade of GRK investigations will likely witness studies designed to address the generality of the signal switch model of GPCR phosphorylation and the existence of novel GRK substrates and binding proteins. Such studies have the potential to greatly expand our understanding of the cellular functions of GRKs.
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